Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.
OBJECTIVE
The pharmacokinetics of etoposide were studied in cancer patients with brain metastases treated with high-dose etoposide in order to determine if the pharmacokinetics were altered by the use of dexrazoxane as a rescue agent to reduce the extracerebral toxicity of etoposide.


METHODS
Etoposide plasma levels were determined by HPLC.


RESULTS
The etoposide pharmacokinetics described by a monophasic first-order elimination model were found to be similar to other reported data in other settings and at similar doses.


CONCLUSIONS
The pharmacokinetics of etoposide were unaffected by dexrazoxane rescue.
Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, Winnipeg, Manitoba, Canada R3T 2N2.
Patricia E
PE
Schroeder
Kenneth Francis
KF
Hofland
Peter Buhl
PB
Jensen
Maxwell
M
Sehested
Seppo W
SW
Langer
Brian B
BB
Hasinoff
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000097:blood* / Q000627:therapeutic use; D019540:Area Under Curve; D001932:Brain Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000556:secondary*; D018288:Carcinoma, Small Cell / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism*; D002408:Catheters, Indwelling; D002851:Chromatography, High Pressure Liquid; D005047:Etoposide / Q000008:administration & dosage / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D011929:Razoxane / Q000008:administration & dosage / Q000097:blood
D011929:Razoxane; D005047:Etoposide